Corcept Therapeutics Inc. (CORT) is trading at $102.73, up 82.88 percent or $45.28 during Monday's trading, after announcing that its pivotal Phase 3 trial, ROSELLA, met its primary endpoint.
The stock opened at $94.72 and has traded between $87.58 and $104.73 so far, compared to a previous close of $54.63 on the Nasdaq. Trading volume has surged to 9.62 million shares, far exceeding the average of 1.01 million. Its 52-week range now stands at $20.84 to $104.73.
The study demonstrated that relacorilant plus nab-paclitaxel significantly improved progression-free survival in patients with platinum-resistant ovarian cancer, as assessed by blinded independent central review.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.